FDA Signals Fresh Scrutiny Of Opioid Painkillers

Law360, New York (December 19, 2012, 12:29 PM EST) -- The U.S. Food and Drug Administration said Wednesday it would devote a two-day hearing to the use of opioids in chronic pain, a move that could affect some of the nation’s most widely prescribed drugs and that suggests the FDA is eyeing new restrictions on the highly addictive medications.

The public meeting, scheduled for Feb. 7 and Feb. 8 in Bethesda, Md., will focus on labeling standards and cover a significant amount of ground involving pain diagnosis, abuse of narcotic analgesics and possible dosing limits. The...
To view the full article, register now.